NABOTA 50U Botulinum Toxin Type A

NABOTA 50U Botulinum Toxin Type A

Indication:

• Temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients (Approved in KR, US, EU, Canada)
• Treatment of upper limb spasticity in adult patients (Approved in KR)
• Temporary improvement in the appearance of moderate to severe lateral canthal lines associated with orbicularis oculi activity in adult patients (Approved in KR)
• Treatment of blepharospasm associated with dystonia in adult patients (Approved in KR)
• HI Pure™ Technology (KR patent No.13-39349, US Patent No. 9,512,418)

Nabota is a premium, high-purity Botulinum Toxin Type A developed by Daewoong Pharmaceutical in South Korea for treating fine lines, wrinkles, and muscle tightness. It acts as a faster-acting, often more affordable alternative to Botox, with results appearing within 2–3 days and lasting 4–6 months

• FDA Approval: Approved in the U.S. in 2019, confirming strict safety and efficacy standards.
• International Approval: Approved by the Korean FDA (MFDS) in 2013, EMA in Europe (as Newtox), and Health Canada.
• Global Presence: Approved in over 60 countries, including Australia (as Nuceiva).
• Manufacturing Quality: Produced in accordance with WHO Good Manufacturing Practices (GMP).

Clinical Efficacy & Safety:

• Purpose: Primarily used for treating glabellar frown lines, it has a fast onset, with improvements often visible within 2–5 days.
• Safety Profile: Clinical trials show high efficacy, with common side effects being mild, such as headache or localized pain.
• Administration: It must be administered by licensed medical professionals